There have been tremendous recent advances in the pharmacotherapy, dose regimens, and combinations used to treat cancer and for the treatment or prevention of the spread of disease. As a direct result of these advances, there are an increasing number of cancer survivors, although research dealing with chemotherapy-induced pain is still in its early

Robert B. Raffa, Ph.D. is Professor and Chair within the Department of Pharmaceutical Sciences at Temple University School of Pharmacy, in Philadelphia, Pennsylvania.

Ronald J. Tallarida, Ph.D. is Professor of Pharmacology at Temple University School of Medicine in Philadelphia, Pennsylvania.

Frank Porreca, Ph.D. is Professor of Pharmacology and Anesthesiology at Temple University in Philadelphia, Pennsylvania.

Joseph V. Pergolizzi, Jr., M.D. is Adjunct Assistant Professor at Johns Hopkins University School of Medicine in Baltimore, Maryland.

Chemotherapy-Induced Neuropathic Pain: Clinical Features. Assessment and Grading of Cancer Chemotherapy-Induced Neuropathic Pain. Chemotherapy-Induced Peripheral Neuropathy: Review of Clinical Studies. Orofacial Neuropathy and Pain in Cancer Patients. Cancer Chemotherapy-Induced Neuropathic Pain: The Underlying Peripheral Neuropathy. Bedside to Bench: Research on Chemotherapy-Induced Neuropathic Pain. In Vivo Models and Assessment of Pharmacotherapeutics for Chemotherapy-Induced Neuropathic Pain. Drug Treatment for Chemotherapy-Induced Neuropathic Pain: Amitriptyline as an Example. Experimental Design and Analysis of Drug Combinations Applicable to Chemotherapy-Induced Neuropathic Pain. Central Neuromodulation for Chemotherapy-Induced Neuropathic Pain. Nerve Decompression for Chemotherapy-Induced Neuropathic Pain.